SCHEMBL3968141

SCHEMBL3968141

CC1=CC(=O)C(CO)=CC1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.59
PLK1 P53350 2/20 0.41
PLK2 Q9NYY3 2/20 0.41
EEF2K O00418 1/20 0.41
MEN1 O00255 2/20 0.33
USP2 O75604 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 2/20 0.33
BLM P54132 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
RAB9A P51151 1/20 0.33
TXNRD1 Q16881 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Xyloquinone SCHEMBL49964 0.76 PLK1 (0.60) STAT3PLK1PLK2EEF2KMEN1
SCHEMBL6449611 0.74 STAT3 (0.69) STAT3PLK1PLK2EEF2KMEN1
SCHEMBL16622153 0.73 STAT3 (0.55) STAT3PLK1PLK2EEF2K
SCHEMBL9875880 0.73 STAT3 (0.37) STAT3MEN1USP2ALDH1A1GAA
SCHEMBL15396944 0.71 STAT3 (0.77) STAT3PLK1PLK2EEF2KKDM4E
SCHEMBL9629083 0.70 STAT3 (0.36) STAT3MAPTTP53IDO1SMN1; SMN2
SCHEMBL10701770 0.69 STAT3 (0.85) STAT3
SCHEMBL14680308 0.67 STAT3 (0.69) STAT3PLK1PLK2EEF2KMEN1
SCHEMBL17817858 0.67 STAT3 (0.81) STAT3PLK1PLK2EEF2K
SCHEMBL7946964 0.67 PLK1 (0.46) STAT3PLK1PLK2EEF2KMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009046127-A1 DT-DIAPHORASE-ACTIVE AGENTS FOR TREATMENT OF PEDIATRIC TUMORS ALLOS THERAPEUTICS, INC. (US) 2009-04-09 WO disclosed
US-20070203109-A1 Compounds And Compositions For Treatment Of Cancer CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 US disclosed
US-6156744-A DT-diaphorase directed anti-tumor agents CANCER RESEARCH CAMPAIGN TECH (LONDON) 2000-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203109-A1 Compounds And Compositions For Treatment Of Cancer RB1, EHMT1, TP53 STAT3 1625/4885PLK1 1165/4885PLK2 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.